glycylcycline

(redirected from Glycylcyclines)

glycylcycline

(gli-sil-sī-klēn),
One of a class of antibiotics chemically related to the tetracyclines.
Mentioned in ?
References in periodicals archive ?
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006; 58(2):256-65.
Dardi Charan Kaur et al also observed that none of their 36 isolates were resistant to antimicrobial category like glycopeptides, glycylcyclines and fucidanes.
Percentage of low resistance was seen in carbapenems, aminoglycosides (only amikacin), glycylcyclines (tigecycline), cephamycins (cefoxitin), quinolone (levofloxacin), phosphonic acids (fosfomycin), antipseudomonal penicillins + [beta]-lactamase inhibitor (pip/tazo), and fluoroquinolones (ciprofloxacin) which can be considered for treatment of Klebsiella species in Mthatha.
[18] European Medicines Agency (EMA), "Use of glycylcyclines in animals in the European Union: development of resistance and possible impact on human and animal health," http://www.ema.europa.eu/docs/en_GB/document_library/ Report/2013/07/WC500146814.pdf.
The market can be segmented according to the major antibiotic agent used in the preparation, drug classes such as macrocyclics, cephalosporins, glycopeptides, carbapenems and glycylcyclines, and the type of topical condition.
Tigecycline (GAR-936) is the 9-t-butylglycylamino derivative of minocycline, a new generation of tetracyclines called glycylcyclines. These glycylcyclines overcome tetracycline resistance due to both ribosomal protection and efflux determinants.
baumannii infection, including carbapenems, polymyxins, tetracyclines and glycylcyclines, aminoglycosides, fluoroquinolones, and various combination therapies.
Tigecycline, the first of a new class of broad-spectrum antibiotics (the glycylcyclines), has been licensed in South Africa for the parenteral treatment of adult patients with complicated intraabdominal infections (clAIs) and complicated skin and soft-tissue infections (cSSTIs).
Indeed, there have been a handful of new antibiotics that have been developed over the past decade, such as the lipopeptides (daptomycin), glycylcyclines (tigecycline), oxazolidinones (linezolid) and streptogramins (quinupristin/dalfopristin).
Tigecycline, the first of a new class of broad-spectrum antibiotics, the glycylcyclines, was recently licensed in South Africa for the parenteral treatment of adult patients with complicated intra-abdominal infections (cIAIs) and complicated skin and soft-tissue infections (cSSTIs).
Tigecycline, the first of a novel class of broad-spectrum antibiotics, the glycylcyclines, was recently licensed in South Africa for the parenteral treatment of adult patients with complicated skin and soft-tissue infections (cSSTIs) and complicated intra-abdominal infections (cIAIs).
In this scenario, the development of a new class of antimicrobial agents, glycylcyclines, represented by tigecycline, a 9-t-butylglyclamide derivative of minocycline is a significant advancement (2-5).